| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/5/2611:00 AM | $0.33 | $5.51GAAP | +1,570% | -15% | $6.69B | $1.19B | ⚠ Check | +16% | |
| Q2 '26 | 8/6/2611:00 AM | $0.31 | $4.91GAAP | +1,484% | +806% | $5.81B | $1.16B | ⚠ Check | +25% | |
| Q1 '26 | 5/7/2611:00 AM | $0.17 | $0.08GAAP | -51.2% | -73% | $4.71B | $0.90B | ⚠ Check | +25% | |
| Q4 '25 | 2/17/2611:00 AM | $0.44 | $0.05GAAP | -88.6% | -94% | $4.40B | $1.06B | ⚠ Check | +15% | |
| Q3 '25 | 11/6/2511:00 AM | $0.46 | $0.65GAAP | +40.4% | +123% | $4.21B | $1.02B | ⚠ Check | +25% | |
| Q2 '25 | 8/7/2511:00 AM | $0.36 | $0.54GAAP | +50.6% | +75% | $3.82B | $0.93B | ⚠ Check | +19% | |
| Q1 '25 | 5/8/2511:00 AM | $0.23 | $0.31GAAP | +34.8% | +7% | $0.75B | $0.72B | -4.5% | +19% |
⚠ Potential error in calculation, check manually. The two revenue figures may be in different units or currencies.
GAAP = diluted EPS as filed with the SEC.